Recent developments in drug delivery to prolong allograft survival in lung transplant patients

Drug Development and Industrial Pharmacy

Volumn 35, Issue 3, 2009, Pages 259-271

  Watts, Alan B ^a   Williams III, Robert O ^a   Peters, Jay I ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Calcineurin inhibitor; Cyclosporine; Immunosuppressant; Lung transplant; Poorly water soluble drug; Tacrolimus

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; BASILIXIMAB; BETA CYCLODEXTRIN; BUDESONIDE; CALCINEURIN INHIBITOR; CASTOR OIL; CHITOSAN; CREMOPHOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DEXTRIN; DODECYL SULFATE SODIUM; FLUTICASONE PROPIONATE; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; LACTOSE; MACROGOL; MACROGOL STEARATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYFROTIC; POLOXAMER; POLYGLACTIN; POLYLACTIC ACID; PREDNISOLONE; PROPYLENE GLYCOL; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ANAPHYLAXIS; BONE MARROW SUPPRESSION; BRONCHIOLITIS; CHRONIC GRAFT REJECTION; CUSHING SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; FIRST PASS EFFECT; GRAFT SURVIVAL; HUMAN; INFECTION SENSITIVITY; INTERSTITIAL PNEUMONIA; LUNG ALVEOLITIS; LUNG HEMORRHAGE; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SOLUBILIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; TACROLIMUS; TREATMENT OUTCOME;

EID: 61649093327     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802282904     Document Type: Review

References (100)

1. Aliabadi, H. M., Mahmud, A., Sharifabadi, A. D., & Lavasanifar, A. (2005). Micelles of methoxy poly(ethylene oxide)-b-poly(ε- caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release, 104, 301-311.
2. Alloway, R., Steinberg, S., Khalil, K., Gourishankar, S., Miller, J., Norman, D., Harihara, S., Pirsch, J., Matas, A., Zaltzman, J., Wisemandle, K., Fitzsimmons, W., & First, M. R. (2005). Conversion of stable kidney transplant recipients from a twice daily prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant. Proc., 37, 867-870.
3. Antignac, M., Hulot, J. S., Boleslawski, E., Hannoun, L., Touitou, Y., Farinotti, R., & Urien, P. (2005). Population pharmacokinetics of tacrolimus in full live transplant patients: Modelling of the post-operative clearance. Eur. J. Clin. Pharmacol., 16, 409-416.
4. Arima, H., Yunomae, K., Miyake, K., Irie, T., Hirayama, F., & Uekama, K. (2001). Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J. Pharm. Sci., 90, 690-701.
5. Arulsudar, N., Subramanian, N., Mishra, P., Sharma, R. K., & Murthy, R. S. R. (2003). Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine. J. Drug Target., 11(3), 187-196.
6. Borro, J. M., Sole, A., De la Torre, M., Pastor, A., & Tarazona, V. (2005). Steroid withdrawal in lung transplant recipients. Transplant. Proc., 37, 3991-3993.
7. Brock, M. V., Borja, M. C., Ferber, L., Orens, J. B., Anzcek, R. A., Krishnan, J., Yang, S. C., & Conte, J. V. (2001). Induction therapy in lung transplantation: A prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant., 20(12), 1282-1290.
8. Burckart, G. J., Smaldone, G. C., Eldon, M. A., Venkataramanan, R., Dauber, J., Zeevi, A., McCurry, K. R., McKaveney, T., Corcoran, T. E., Griffith, B. P., & Iacono, A. T. (2003). Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm. Res., 20(2), 252-256.
9. Canadas, O., Guerrero, R., Garcia-Canero, R., Orellana, G., Menendez, M., & Casals, C. (2004). Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry (Mosc), 43(30), 9926-9938.
10. Carby, M., & Lyster, H. (2006). A novel approach to immunosuppression: Targeting the alloimmune mechanisms of graft rejection. Curr. Opin. Organ Trans., 11, 496-501.
11. Chen, X., Young, T. J., Sarkari, M., Williams III, R. O., & Johnston, K. P. (2002). Preparation of cyclosporine A nanoparticles by evaproative precipitation into aqueous solution. Int. J. Pharm., 242, 3-14.
12. Corcoran, T. E. (2006). Inhaled delivery of aerosolized cyclosporine. Adv. Drug Deliv. Rev., 58(9-10), 1119-1127.
13. Corcoran, T. E., Smaldone, G. C., Dauber, J. H., Smith, D. A., McCurry, K. R., Burckart, G. J., Zeevi, A., Griffith, B. P., & Iacono, A. T. (2004). Preservation of post-transplant lung function with aerosol cyclosporin. Eur. Respir. J., 23, 378-383.
14. Corcoran, T. E., Venkataramanan, R., Mihelc, K. M., Marcinkowski, A. L., Ou, J., McCook, B. M., Weber, L., Carey, M. E., Paterson, D. L., Pilewski, J. M., McCurry, K. R., & Husain, S. (2006). Aerosol deposition of lipid complex amphotericin-B (abelcet) in lung transplant recipients. Am. J. Transplant., 6(11), 2765-2773.
15. Curran, M. P., & Keating, G. M. (2005). Mycophenolate sodium delayed release. Drugs, 65(6), 799-805.
16. Dai, J., Nagai, T., Wang, X., Zhang, T., Meng, M., & Zhang, Q. (2004). pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm., 280, 229-240.
17. DeCamp, M. M. (2006). Inhaled cyclosporine - a breath of fresh air? New Engl. J. Med., 354(2), 191-193.
18. De Soyza, A., Fisher, A. J., Small, T., & Corris, P. A. (2001). Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am. J. Respir. Crit. Care Med., 164(7), 1209-1212.
19. Egan, J. J. (2004). Obliterative bronchiolitis after lung transplantation: A repetitive multiple injury airway disease. Am. J. Respir. Crit. Care Med., 170(9), 931-932.
20. Eisen, H. J., Hobbs, R. E., Davis, S. F., Carrier, M., Mancini, D. M., Smith, A., Valantine, H., Ventrua, H., Mehra, M., Vachiery, J., Rayburn, B. K., Canver, G. C., Laufer, G., Costanzo, M., Copeland, J., Dureau, G., Franzier, O. H., Dorent, R., Hauptman, P. J., Kells, C., Masters, R., Michaud, J., Paradis, I., Renlund, D. G., Vanhaecke, J., Mellein, B., & Mueller, E. A. (2001). Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation. Transplantation, 71(1), 70-78.
21. El-Shabouri, M. H. (2002). Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm., 249, 101-108.
22. Estenne, M., & Hertz, M. I. (2002). Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med., 166(4), 440-444.
23. First, M. R., & Fitzsimmons, W. E. (2004). Modified release tacrolimus. Yonsei Med. J., 45(6), 1127-1131.
24. Floren, L., Bekersky, I., Benet, L., Mekki, Q., Dressler, D., Lee, J., Roberts, J., & Hebert, M. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther., 62(1), 41-49.
25. Florman, S., Alloway, R., Kalayoglu, M., Lake, K., Bak, T., Klein, A. Klintmalm, G., Busque, S., Brandenhagen, D., Lake, J., Wisemandle, K., Fitzsimmons, W., & First, M. R. (2005). Conversion of stable liver transplant recipients from a twice daily prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant. Proc., 37(2), 1211-1213.
26. Francis, M. F., Cristea, M., Yang, Y., & Winnik, F. M. (2005). Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across caco-2 cells. Pharm. Res., 22(2), 209-219.
27. Garrity, E. R., & Mehra, M. R. (2004). An update on clinical outcomes in heart and lung transplantation. Transplantation, 77(9), S68-S74.
28. Gilbert, B. E., Black, M. B., Bennick, J., Montgomery, C., & Knight, V. (1997). Cyclosporin A liposome aerosol: Lack of acute toxicity in rats with a high incidence of underlying pneumonitis. Inhal. Toxicol., 9, 717-730.
29. Goorhuis, J. F., Scheenstra, R., Peeters, P., & Albers, M. (2006). Buccal vs. Nasogastric tube administration of tacrolimus after pediatric liver transplantation. Pediatr. Transplant., 10, 74-77.
30. Gref, R., Quellec, P., Sanchez, A., Calvo, P., Dellacherie, E., & Alonso, M. J. (2001). Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm., 51, 111-118.
31. Guo, J., Wu, T., Ping, Q., Chen, Y., & Shen, J. (2005). Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv., 12, 35-39.
32. Hebert, M. F. (1997). Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Deliv. Rev., 27(2-3), 201-214.
33. Holt, D. W., & Johnston, A. (1997). Cyclosporine microemulsion. A guide to usage and monitoring. BioDrugs, 7, 175-197.
34. Hu, J., Johnston, K. P., & Williams III, R. O. (2004). Nanoparticle engineering process of enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm., 30(3), 233-245.
35. Iacono, A. T., Corcoran, T. E., Griffith, B. P., Grgurich, W. F., Smith, D. A., Zeevi, A., Smaldone, G. C., McCurry, K. R., Johnson, B. A., & Dauber, J. H. (2004). Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur. Respir. J., 23, 384-390.
36. Iacono, A. T., Johnson, B. A., Grgurich, W. F., Youssef, J. G., Corcoran, T. E., Seiler, D. A., Dauber, J. H., Smaldone, G. C., Zeevi, A., Yousem, S. A., Fung, J. J., Burckart, G. J., McCurry, K. R., & Griffith, B. P. (2006). A randomized trial of inhaled cyclosporine in lung-transplant recipients. New Engl. J. Med., 354(2), 141-150.
37. Ide, N., Nagayasu, T., Matsumoto, K., Tagawa, T., Tanaka, K., Taguchi, T., Sumida, Y., & Nakashima, M. (2007). Efficacy and safety of inhaled tacrolimus in rat lung transplantation. J. Thorac. Cardiovasc. Surg., 133, 548-553.
38. Ingu, A., Komastu, K., Ichimiya, S., Sato, N., Hirayama, Y., Morikawa, M., & Tomio, A. (2005). Effects of inhaled FK 506 on the suppression of acute rejection after lung transplantation: Use of a rat orthotopic lung transplantation model. J. Heart Lung Transplant., 24(5), 538-543.
39. Italia, J. L., Bhardwaj, V., & Ravi Kumar, M. N. V. (2006). Disesae, destination, dose, and delivery aspects of ciclosporin: The state of the art. Drug Discov. Today, 11(17), 846-854.
40. Jain, A. B., & Fung, J. J. (1996). Cyclosporin and tacrolimus in clinical transplantation - a comparative review. Clin. Immunother., 5, 351-373.
41. Keenan, R. J., Iacono, A. T., Dauber, J. H., Zeevi, A., Yousem, S. A., Ohori, N. P., Burckart, G. J., Kawai, A., Smaldone, G. C., & Griffith, B. P. (1997). Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J. Thorac. Cardiovasc. Surg., 113(2), 335-341.
42. Keenan, R. J., Konishi, H., Kawai, A., Paradis, I. L., Nunley, D. R., Iacono, A. T., Hardesty, R. L., Weyant, R. J., & Griffith, B. P. (1995). Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann. Thorac. Surg., 60(3), 580-584.
43. Knoop, C., Haverich, A., & Fisher, S. (2004). Immunosuppressive therapy after human lung transplantation. Eur. Respir. J., 23, 159-171.
44. Knoop, C., Thiry, P., Saint-Marcoux, F., Rousseau, A., Marquet, P., & Estenne, M. (2005). Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am. J. Transplant., 5(6), 1477-1482.
45. Lamprecht, A., Yamamoto, H., Takeuchi, H., & Kawashima, Y. (2005). A pH-sensitive microsphere for the colon delivery of tacrolimus containing nanoparticles. J. Control. Release, 104, 337-346.
46. Lee, M. A. (2003). Transplantation: Drug aspects of immunosuppression. Hosp. Pharmacist, 10, 201-207.
47. Lee, E., Lee, S., Choi, H., & Kim, C. (2001). Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int. J. Pharm., 218, 125-131.
48. Letsou, G. V., Safi, H. J., Reardon, M. J., Ergenoglu, M., Li, Z., Klonaris, C. N., Baldwin, J. C., Gilbert, B. E., & Waldrep, J. C. (1999). Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg., 68(6), 2044-2048.
49. Li, Y., Zhu, K. J., Zhang, J. X., Jiang, H. L., Liu, J. H., Hao, Y. L., Yasuda, H., Ichimaru, A., & Yamamoto, K. (2005). In vitro and in vivo studies of cyclosproin A-loaded microspheres based on copolymers of lactide and ε-caprolactone: Comparison with conventional PLGA microspheres. Int. J. Pharm., 295, 67-76.
50. Liu, C., Wu, J., Shi, B., Yuanxing, Z., Gao, T., & Yuanying, P. (2006). Enhancing the bioavailability of cyclosporine A using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev. Ind. Pharm., 32(1), 115-123.
51. Lo, A., & Burckart, G. J. (1999). P-glycoprotein and drug therapy in organ transplantation. J. Clin. Pharmacol., 39, 995-1005.
52. McAllister, S. M., Alpar, H. O., Teitelbaum, Z., & Bennett, D. B. (1996). Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung? Adv. Drug Deliv. Rev., 19(1), 89-110.
53. McWilliams, T. J., Levvey, B. J., Russell, P. A., Milne, D. G., & Snell, G. I. (2003). Interstitial pneumonitis associated with sirolimus: A dilemma for lung transplantation. J. Heart Lung Transplant., 22(2), 210-213.
54. Meier-Kriesche, H. U., Li, S., Gruessner, R. W. G., Fung, J. J., Bustami, R. T., Barr, M. L. & Leichtman, A. B. (2006). Immunosuppression: Evolution in practice and trends, 1994-2004. Am. J. Transplant., 6(5p2), 1111-1131.
55. Meissner, Y., Pellequer, Y., & Lamprecht, A. (2006). Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int. J. Pharm., 316, 138-143.
56. Metha, M. U., Venkataramanan, R., Burckart, G. J., Ptachcinski, R. J., Delamos, B., Stachak, S., Van Thiel, D. H., Iwatsuki, S., & Startzl, T. E. (1988). Effect of bile on cyclosporin absorprtion in liver transplant patients. Br. J. Clin. Pharmacol., 25, 579-584.
57. Mitruka, S. N., Pham, S. M., Zeevi, A., Li, S., Cai, J., Burckart, G. J., Yousem, S. A., Keenan, R. J., & Griffith, B. P. (1998). Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg., 115(1), 28-37.
58. Mitruka, S. N., Won, A., McCurry, K. R., Zeevi, A., McKaveney, T., Venkataramanan, R., Iacono, A. T., Griffith, B. P., & Burckart, G. J. (2000). In the lung aerosol cyclosporine provides a regional concentration provides a regional concentration advantage over intramuscular cyclosporine. J. Heart Lung Transplant., 19(10), 969-975.
59. Moffatt, S. D., McAlister, V., Calne, R. Y., & Metcalfe, S. M. (1999). Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Transplantation, 67(9), 1205-1208.
60. Mohammad, R. A., & Klein, K. C. (2006). Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann. Pharmacother., 40(12), 2148-2154.
61. Morishita, Y., Hirayama, Y., Miyayasu, K., Tabata, K., Kawamura, A., Ohkubo, Y., & Mutoh, S. (2005). FK506 aerosol locally inhibits antigen-induced airway inflammation in guinea pigs. Int. Arch. Allergy Immunol., 136, 372-378.
62. Mueller, X. M. (2004). Drug immunosuppression therapy for adult heart transplantation. Part 1: Immune response to allograft and mechanism of action of immunosuppressants. Ann. Thorac. Surg., 77(1), 354-362.
63. Mulligan, M. S., & Wood, D. S. (2003). Optimizing lung transplant immunosuppression: Beyond calcineurin inhibition. J. Thorac. Cardiovasc. Surg., 125(4), 784-786.
64. Murata, S., Shiomojo, F., Tokunaga, Y., & Hata, T. (2002). USPO.
65. Naef, R., Schmid, C., Hofer, M., Minder, S., Speich, R., & Boehler, A. (2007). Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients. Respiration, 74, 418-422.
66. Nathan, S. D., Ross, D. J., Zakowski, P., Kass, R. M., & Koerner, S. K. (1994). Utility of inhaled pentamidine prophylaxis in lung transplant recipients. Chest, 105(2), 414-417.
67. O'Grady, J. G., Burroughs, A., Hardy, P., Elboume, D., & Truesdale, A. (2002). Tacrolimus versus microemulsified ciclosproin in liver transplantation: The TMC randomised controlled trial. Lancet, 360, 1119-1125.
68. Overhoff, K. A., McConville, J. T., Yang, W., Johnston, K. P., Peters, J. I., & Williams III, R. O. (2008). Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm. Res., 25, 167-175.
69. Peters, J. I., Purvis, T., Pollack, M., Angel, L., & Williams III, R. (2007). In vitro efficacy and in vivo safety of inhaled nanoparticles of tacrolimus. Chest, 132(4), 430b.
70. Pham, P. T., Pham, P. T., Danovitch, G. M., Ross, D. J., Gritsch, H. A., Kendrick, E. A., Singer, J., Shah, T., & Wilkinson, A. H. (2004). Sirolimus-associated pulmonary toxicity. Transplantation, 77(8), 1215-1220.
71. Reams, D., Rea, J., Davis, D., & Palmer, S. (2001). Abstract: Utility of sublingual tacrolimus in cystic fibrosis patients after lung transplantation. J. Heart Lung Transplant., 20(2), 207-208.
72. Romero, I., Jimenez, C., Gil, F., Escuin, F., Ramirez, E., Fudio, S., Borobia, A., & Carcas, A. (2008). Sublingual administration of tacrolimus in a renal transplant patient. J. Clin. Pharm. Ther., 33, 87-89.
73. Saitoh, H., Saikachi, Y., Kobayashi, M., Yamaguchi, M., Oda, M., Yuhki, Y., Achiwa, K., Tadano, K., Takahashi, Y., & Aungst, B. J. (2006). Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur. J. Pharm. Biopharm., 28, 34-42.
74. Schrepfer, S., Deuse, T., Fink, J., Haddad, M., & Robbins, R. C. (2008). Abstract: Optimizing aerosolized tacrolimus to prevent cellular and humoral rejection. J. Heart Lung Transplant., 27(2S), S142-S143.
75. Schrepfer, S., Deuse, T., Hoffman, J., Pelletier, M. P., Fischbein, M. P., Reichenspurner, H., & Robbins, R. C. (2007). Inhaled immunosuppression with tacrolimus after airway transplantation. J. Heart Lung Transplant., 26(2S), S258-S259.
76. Schrepfer, S., Deuse, T., Reichenspurner, H., Hoffmann, J., Haddad, M., Fink, J., Fischbein, M. P., Robbins, R. C., & Pelletier, M. P. (2007). Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am. J. Transplant., 7(7), 1733-1742.
77. Shi, W., Liu, T., Xie, L., & Wang, S. (2005). FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival. Curr. Eye Res., 30, 969-976.
78. Silva, H. T., Yang, H. C., Abouljoud, M., Kuo, P. C., Wisemandle, K., Bhattacharya, P., Dhadda, S., Holman, J., Fitzsimmons, W., & First, M. R. (2007). One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am. J. Transplant., 7(3), 595-608.
79. Sinswat, P., Overhoff, K. A., McConville, J. T., Johnston, K. P., & Williams III, R. O. (2008). Nebulization of nanoparticulate amorphous or crystalline tacrolimus - single-dose pharmacokinetics study in mice. Eur. J. Pharm. Biopharm., 69(3), 1057-1066.
80. Speich, R., Boehler, A., & Russi, E. W. (1997). A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans. Respiration, 64(5), 375-380.
81. Takamatsu, Y., Ishizu, M., Ichinose, I., Ogata, K., Onoue, M., Kumagaura, M., Suzumiya, J., & Tamura, K. (2001). Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant., 28, 421-423.
82. Takao, M., Higenbottam, T. W., & Audley, T. (1995). Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant. Proc., 27(1), 1284-1285.
83. Tamura, S., Ohike, A., Ibuki, R., Amidon, G. L., & Yamashita, S. (2002). Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci., 91(3), 719-729.
84. Tan, K. K. C., Trull, A. K., Uttridge, J. A., & Wallwork, J. (1995). Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur. J. Clin. Pharmacol., 48, 285-289.
85. Trulock, E. P., Christie, J. D., Edwards, L. B., Boucek, M. M., Aurora, P., Taylor, D. O., Dobbels, F., Rahmel, A. O., Keck, B. M., & Hertz, M. I. (2007). Registry of the international society for heart and lung transplantation: Twenty-fourth official adult lung and heart-lung transplantation report - 2007. J. Heart Lung Transplant., 26, 782-795.
86. Uber, P. A., & Mehra, M. R. (2007). Induction therapy in heart transplantation: Is there a role? J. Heart Lung Transplant., 26(3), 205-209.
87. Varela, M. C., Guzman, M., Molpeceres, J., del Rosario Aberturas, M., Rodriguez-Puyol, D., & Rodriguez-Puyol, M. (2001). Cyclosporine-loaded polyaprolactone nanoparticles: Immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Biopharm., 12, 471-478.
88. Vaughn, J. M., McConville, J. T., Crisp, M. T., Johnston, K. P., & Williams III, R. O. (2006). Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev. Ind. Pharm., 32, 559-567.
89. Venkataramanan, R., Burckart, G. J., Ptachcinski, R. J., Blaha, R., Logue, L. W., Bahnson, A., . Giam, C. S., & Brady, J. E. (1986). Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am. J. Health-Syst. Pharm., 43(11), 2800-2802.
90. Verleden, G. M., Dupont, L. J., Van Raemdonck, D., & Vanhaecke, J. (2003). Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J. Heart Lung Transplant., 22(8), 908-913.
91. Virmani, R., Guagliumi, G., Farb, A., Giuseppe, M., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O., & Kolodgie, F. D. (2004). Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation, 109, 701-705.
92. Volcheck, G. W., & Van Dellen, R. G. (1998). Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: Case report and review. Ann. Allergy Asthma Immunol., 80, 159-163.
93. Wang, Q., Uno, T., Miyamoto, Y., Hara, Y., Kitazawa, Y., Lu, F. Z., Funeshima, N., Fujino, M., Yamamoto, H., Takenaka, H., Kawashima, Y., & Li, X. K. (2004). Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. Am. J. Transplant., 4(5), 721-727.
94. Wang, T., Noonberg, S., Steigerwalt, R., Lynch, M., Kovelesky, R. A., Rodriguez, C. A., Sprugel, K., & Turner, N. (2007). Preclincial safety evaluation of inhaled cyclosporine in propylene glycol. J. Aerosol Med., 20(4), 417-428.
95. Westney, G. E., Kesten, S., Hoyos, D., Chapparro, C., Winton, T., & Maurer, J. R. (1996). Aspergillus infection in single and double lung transplant recipients. Transplantation, 61, 915-919.
96. Whitford, H., Walters, E. H., Levvey, B., Kotsimbos, T., Orsida, B., Ward, C., Pais, M., Reid, S., Williams, T., & Snell, G. (2002). Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: A double-blind, placebo-controlled trial. Transplantation, 73(11), 1793-1799.
97. Wnek, G. E., & Bowlin, G. L. (2004). Encyclopedia of biomaterials and biomedical engineering. New York: Marcel Dekker.
98. Yamashita, K., Nakate, T., Okimoto, K., Ohike, A., Tokunaga, Y., Ibuki, R., Higaki, K., & Kimura, T.(2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm., 267, 79-91.
99. Yuan, X., Yuan, Y., Jiang, W., Liu, J., Tian, E., Shun, H., Huang, D., Yuan, X., Li, H., & Sheng, J. (2008). Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int. J. Pharm., 349, 241-248.
100. Zuskin, E., Bouhuys, A., & Sari, M. (1981). Lung function changes by ethanol inhalation. Clin. Exp. Allergy, 11(3), 243-248.